N-叔丁基-3-硝基苯磺酰胺 | 424818-25-7

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-叔丁基-3-硝基苯磺酰胺
• 英文名称: N-(dimethylethyl)-3-nitrobenzenesulfonamide
• 英文别名: N-tert-butyl-3-nitrobenzenesulfonamide；3-nitro-benzenesulfonic acid tert-butylamide；3-Nitro-benzolsulfonsaeure-tert-butylamid；N-t-butyl 3-nitrobenzenesulfonamide
• CAS: 424818-25-7
• 化学式: C₁₀H₁₄N₂O₄S
• mdl: MFCD01985492
• 分子量: 258.298
• InChiKey: UHFXZEXYBBMXBY-UHFFFAOYSA-N

物化性质

• 熔点：
  >157°C (dec.)
• 沸点：
  385.7±44.0 °C(Predicted)
• 密度：
  1.282±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2935009090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
N-t-Butyl 3-nitrobenzenesulfonamide
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P302+P352: IF ON SKIN: Wash with soap and water
P321: Specific treatment (see on this label)
P405: Store locked up

---

Section 3. Composition/information on ingredients.
N-t-Butyl 3-nitrobenzenesulfonamide
Ingredient name:
CAS number: 424818-25-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H14N2O4S
Molecular weight: 258.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-叔丁基-3-硝基苯磺酰胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 铁粉 、 氯化铵 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 6.0h， 生成 3-[(2-氯-5-甲基-4-嘧啶基)氨基]-N-(叔丁基)苯磺酰胺
  参考文献：
  名称：

  基于 Fedratinib 部分的 Janus 激酶 (JAK) 和组蛋白去乙酰化酶 (HDAC) 双特异性抑制剂的探索，用于治疗血液系统恶性肿瘤和实体癌

  摘要：

  Janus 激酶 (JAK)–STAT 通路的反馈激活导致实体癌对组蛋白脱乙酰酶 (HDAC) 抑制剂不敏感。在此，设计并合成了一系列基于 fedratinib 部分的新型 2-amino-4-phenylaminopyrimidine JAK/HDAC 双靶点抑制剂。其中，21和30在纳摩尔水平上有效抑制 HDAC3/6 和 JAK1/2，并且对 JAK2 对一组 76 种激酶表现出出色的选择性。21和30在血液恶性肿瘤和实体癌中表现出显着的抗增殖活性，这得到了 JAK-STAT 和 HDAC 通路阻断和促凋亡活性的认可。基于出色的血浆稳定性和口服生物利用度，21和30有效地抑制了HEL和A549异种移植模型的肿瘤生长。综上所述，上述结果证实了JAK/HDAC双靶点抑制剂为血液恶性肿瘤和实体癌的靶向治疗提供了有价值的线索。

  DOI：

  10.1021/acs.jmedchem.3c00036
• 作为产物：
  描述：

  硝基苯 在 氯磺酸 、 氯化亚砜 作用下， 以 乙酸乙酯 为溶剂， 反应 22.0h， 生成 N-叔丁基-3-硝基苯磺酰胺
  参考文献：
  名称：

  [EN] A PROCESS FOR THE DIRECT SYNTHESIS OF FEDRATINIB INTERMEDIATE
  [FR] PROCÉDÉ DE SYNTHÈSE DIRECTE D'INTERMÉDIAIRE DE FEDRATINIB

  摘要：

  本公开涉及一种直接合成Fedratinib中间体的方法。特别地，本公开涉及一种直接合成3-氨基-N-(叔丁基)苯磺酰胺的方法。本公开方法具有多种优点，如操作条件方便、节省时间、易于纯化、操作成本低、产率和效率高，因此该方法在工业上是可行的。本公开方法使用的是无毒、廉价且易得的试剂，使得该方法具有成本效益、经济环保的特点。

  公开号：

  WO2022269384A1

文献信息

• [EN] POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS<br/>[FR] PUISSANTS DOUBLES INHIBITEURS DE BRD4 ET DE KINASE À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES ANTICANCÉREUX
  申请人：H LEE MOFFITT CANCER CT & RES

  公开号：WO2016022460A1

  公开（公告）日：2016-02-11

  Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.

  本文披露了一些抑制BRD4的化合物及其在癌症治疗中的应用。还披露了筛选BRD4选择性抑制剂的方法。在某些方面，披露了Formula I-IV的化合物。
• [EN] BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS<br/>[FR] INHIBITEURS DE BRD4-KINASE À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES ANTICANCÉREUX
  申请人：H LEE MOFFITT CANCER CENTER & RES INST INC

  公开号：WO2017066428A1

  公开（公告）日：2017-04-20

  Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

  本文披露了一些抑制BDR4的化合物及其在癌症治疗中的应用。还披露了筛选BDR4选择性抑制剂的方法。在某些方面，披露了公式I至IV的化合物。
• Microwave‐Assisted Synthesis, Antimicrobial, and Cytotoxicity Activity of <i>N</i> ‐ <i>tert</i> ‐butyl‐3‐{[2‐(arylamino)pyrimidin‐4‐yl]amino} Benzenesulfonamides
  作者：Shivaji B. Patwari、Medari S. Murali、Vivekanand B. Jadhav

  DOI：10.1002/jhet.3364

  日期：2018.12

  reaction for the synthesis of N‐tert‐butyl‐3‐[2‐(arylamino)pyrimidin‐4‐yl]amino} benzenesulfonamide 5 by the treatment of N‐tert‐butyl‐3‐[(2‐chloropyrimidin‐4‐yl)amino] benzenesulfonamide 4 with different aromatic amines in the presence of Cs2CO3 and in DMF under microwave conditions. All the eight compounds 5a–h were evaluated for their antibacterial, antifungal, and cytotoxic activities. Among

  一种新颖的合成方法已被开发以用于合成钯催化的Buchwald-Hartwig的型反应ñ -叔丁基-3 - [2-（芳基氨基）嘧啶-4-基]氨基}苯磺酰胺5通过治疗ñ -叔丁基-3 - [（2-氯嘧啶-4-基）氨基]苯磺酰胺4与Cs的存在不同的芳族胺2 CO 3和DMF中在微波条件下。对所有8种化合物5a–h的抗菌，抗真菌和细胞毒性活性进行了评估。在标题化合物中，5c和5d对革兰氏阳性和革兰氏阴性细菌均显示出有效的活性。化合物5c和5d表现出良好的抗真菌活性，并且化合物5c，5d和5f表现出显着的细胞毒性活性。
• 用于抑制激酶活性的二苯氨基嘧啶类化合物
  申请人：深圳市塔吉瑞生物医药有限公司

  公开号：CN109232440B

  公开（公告）日：2020-09-11

  用于抑制激酶活性的二苯氨基嘧啶类化合物。本发明提供了一种取代的二苯氨基嘧啶类化合物的药物组合物及其用途，所述的化合物如式(I)所示化合物，或其药学上可接受的盐、前药、水合物或溶剂化合物、晶型、N‑氧化物和各种非对映体。本发明化合物可用于治疗可用JAK2激酶抑制剂治疗的疾病。
• 一种HDAC、JAK和BET三靶点抑制剂及其制备方法和应用
  申请人：山东大学

  公开号：CN113754591A

  公开（公告）日：2021-12-07

  本发明公开了一种HDAC、JAK和BET三靶点抑制剂及其制备方法和应用。所述的HDAC、JAK和BET三靶点抑制剂，其结构通式为(I)或(II)所示。本发明还提供该类化合物的制备方法以及在制备预防或治疗与HDAC、JAK和BET活性或表达异常相关的疾病的药物中的应用。